TrialOncology research2025

Comprehensive molecular characterization to predict immunotherapy response in advanced biliary tract cancer: a phase II trial of pembrolizumab.

Ryul Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.